Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases (Q38972531)

8 September 2017

1 reference

title

Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases (English)

1 reference

8 September 2017

1

Emma D Deeks

1 reference

8 September 2017

publication date

4 October 2016

1 reference

8 September 2017

1 reference

8 September 2017

volume

30

1 reference

8 September 2017

issue

6

1 reference

8 September 2017

page(s)

607-617

1 reference

The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III st

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised pla

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Overview of safety of non-biologic and biologic DMARDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Adverse reactions to biologic agents and their medical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Challenges and approaches for the development of safer immunomodulatory biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0197-Y

10.1007/S40259-016-0197-Y

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference